Results 51 to 60 of about 16,113,232 (257)

SPHINX31 acts as a SRPK1 inhibitor targeting the ATR/DNA‐PKcs/CHK1 replicative checkpoint to inhibit cell growth in non‐small cell lung cancer

Molecular Oncology, EarlyView.
The kinase SRPK1 directly interacts with the protein TOPBP1 and regulates the pre‐mRNA splicing of WIZ thereby contributing to the activation of the ATR/CHK1 replicative checkpoint in response to replicative stress. This allows cancer cells' genomic stability and survival.
Amani Shreim, Aurelie Genoux, Nadiia Zubchuk, Haoyang Zheng, Perla Salameh, Theo Ziegelmeyer, Fabien Dalonneau, Margot Rouchette, Christiane Oddou, Simona Miron, Helene Polveche, Adiilah Mamode Cassim, Carmen Garrido, Eleni Nikolakaki, Didier Auboeuf, Tao Jia, Sophie Zinn‐Justin, Beatrice Eymin   +17 more
wiley   +1 more source

Mutant p53R273H disrupts PDPK1 homodimerization and contributes to PDPK1 activation

Molecular Oncology, EarlyView.
How mutant p53R273H drives AKT signaling is unclear. We show that p53R273H, but not wild‐type, directly binds PDPK1 via a mutation‐dependent conformational change. This interaction disrupts inhibitory PDPK1 homodimerization and enhances AKT phosphorylation.
Mei Chee Lim, Alvin Kunyao Guo, Yoko Itahana, Srinivasaraghavan Kannan, Valerie Goh, Mingmin Ong, Terina Yan Wen Tay, Weiying Ye, Sabhashina Radha Krishnan, Jun Nishiyama, Chandra S Verma, Koji Itahana   +11 more
wiley   +1 more source

Scientific and Technical Tools for Enhancement of Special Treatment Devices

Вестник войск РХБ защиты
Highlights- nowadays it is impossible to maintain contaminated vehicles and equipment in special decontamination centers nearthe battle line due to far-ranging precision weapons and drones;- promising on-board sets and special treatment devices should be
V. V. Mahniboroda, A. A. Gorjachev, A. E. Krasnov   +2 more
doaj   +1 more source

Special Treatment, 2025.11.(SI)

Journal of Special Treatment, 2025.11.(SI) - full ...
Editorial office of Special Treatment Journal, Különleges Bánásmód Folyóirat, Szerkesztősége, Special Treatment Journal, Editorial office of   +2 more
core   +1 more source

Targeting the EpCAM‐AXL axis to overcome drug resistance in lung cancer

Molecular Oncology, EarlyView.
Lung cancer cells often evade therapy by hijacking signaling pathways. We reveal that cleaved EpCAM (sEpCAM) stabilizes the oncogenic protein AXL, driving NF‐κB and STAT3‐mediated chemoresistance. This EpCAM‐AXL axis identifies a high‐risk patient subset with poor prognosis.
Alexa Guerrero‐Alba, Mark Shacker, Timothy P. Fleming, Michael A. Smith, Ross M. Bremner, Narendra V. Sankpal   +5 more
wiley   +1 more source

Solution of the municipal waste water treatment efficiency in Strážske [PDF]

Acta Montanistica Slovaca, 2005
A special and long lasting problem in the Slovak republic in the substantial hydraulical overloading of some wastewater treatment plants. Because their technology of treatment is inconvenient and the quality of treated water is not according to the ...
Eugen Kovaľ, Magdaléna Bálintová, Natália Kovaliková   +2 more
doaj  

Study on Water Gradient Utilization and Zero Emission Technology in IGCC Power Plant

Zhongguo dianli, 2019
In the first IGCC power plant in China, there are some problems in the operation process such as the water drainage process is not reasonable and the coal gasification and sulfur containing wastewater is difficult to deal with. In view of these problems,
Huoqiang WU, Guoquan YUAN, Yapeng LIU, Xiangping WANG, Jing WANG, Xiangjun LI, Zhihong WU   +6 more
doaj   +1 more source

SPECIAL TREATMENT JOURNAL, 2024. Vol. 10.(SI)

Journal of Special Treatment, 2024.
Különleges Bánásmód, Folyóirat Szerkesztősége, Special Treatment Journal, Editoral Board of, Editoral Board of Special Treatment Journal   +2 more
core   +1 more source

Characterization of therapeutic antibodies targeting lymphatic and vascular resistance factor for the treatment of hypervascularized and highly metastatic cancers

Molecular Oncology, EarlyView.
LVRF (lymphatic and vascular resistance factor) is a VEGFA splice variant upregulated in response to anti‐angiogenic therapy that fosters tumor adaptation through enhanced vascularization, lymphangiogenesis, and metastatic dissemination. Targeting LVRF with fully human neutralizing antibodies disrupts these processes and limits resistant tumor growth ...
Marion David, Arthur Karaulic, Audrey Bennetot, Clémence Fournier, Quentin Odet, Arthur Gouraud, Isabelle Bourget, Cédric Gaggioli, Sandy Giuliano, Frédéric Luciano, Olivier Léger, Zaki Sellam, Gilles Pagès   +12 more
wiley   +1 more source

Overcoming platinum resistance by the disulfiram metabolite CuET in novel preclinical models of human carcinomas

Molecular Oncology, EarlyView.
Cisplatin‐resistant cancer cells survive DNA‐damaging platinum‐based treatment yet remain sensitive to CuET‐induced proteotoxic stress. The distinct mechanism of action allows CuET to overcome and eliminate cisplatin‐resistant tumour cells, unless highly expressed metallothioneins (MTs) interfere with CuET, thereby highlighting MT levels as candidate ...
Stefanos Arampatzis, Tereza Buchtová, Jirina Bartkova, Marie Lund Bay, Christoffer Lynge Halvorsen, Zuzana Machacova, Zdenek Skrott, Martin Mistrik, Ekaterina Dulina, Miguel Andujar‐Sanchez, Estrid Høgdall, Tine Henrichsen Schnack, Claus Høgdall, Berit Jul Mosgaard, Marie Boennelycke, Jacob Brink Laursen, Allan Jensen, Susanne K. Kjær, Tuula Kallunki, Robert Strauss, Jiri Bartek   +20 more
wiley   +1 more source